Why the study?
Fulminant myocarditis requiring peripheral VA-ECMO has a high mortality rate, prompting investigation into outcomes of combined VA-ECMO and Impella support.
Does management at a transplant center improve survival in patients with fulminant myocarditis receiving combined VA-ECMO and percutaneous left ventricular assist device support?
Does management at a transplant center improve survival in patients with fulminant myocarditis receiving combined VA-ECMO and percutaneous left ventricular assist device support?
In patients with fulminant myocarditis requiring combined VA-ECMO and percutaneous ventricular unloading, management at transplant centers is associated with significantly higher survival rates compared to nontransplant centers.
Answers are grounded in this paper and cite their sources.
Associated survival advantage at transplant centers warrants prospective evaluation; leaves open optimal care pathways for fulminant myocarditis on biventricular support.
Fulminant myocarditis requiring peripheral veno-arterial extracorporeal membrane oxygenation (VA-ECMO) has a high mortality rate. We investigated clinical outcomes of combined use of VA-ECMO and percutaneous left ventricular assist device (VAD) (Impella) for fulminant myocarditis in 104 consecutive patients enrolled in the Japan Registry for Percutaneous VAD (J-pVAD) between October 2017 and January 2020. Patients were followed until hospital discharge and predictors of survival were analyzed with a Cox proportional hazards model. The median support duration of combined use of VA-ECMO and Impella (ECMO/Impella) was 6 days, and the median left ventricular ejection fraction improved from 15% to 52% during support ( p < 0.0001). Overall, 66 patients (63%) survived to discharge. Multivariate analysis revealed ECMO/Impella support at a transplant center as an independent predictor of survival ( p = 0.0231). Patients treated at transplant centers had better 60 days survival rates when compared to nontransplant centers (83% vs. 55%, p = 0.005). However, baseline characteristics and treatment strategies differed between the two groups. This real-world national registry database suggested the difference in survival after ECMO/Impella support for fulminant myocarditis between transplant and nontransplant centers, which may indicate hospital variations regarding patient management, although further controlled studies are needed.
No takes yet. Share an insight, caveat, or question.
Toda et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: